Clinical Study on the Use of Huaier Granules for the Treatment of Proteinuria Related to Bevacizumab and Anlotinib in Lung Cancer Patients

Inclusion Criteria: * Age ≥18 years; * Histopathologically confirmed diagnosis of lung cancer; * Receiving Bevacizumab or Anlotinib treatment; * Positive urine protein detection, with 0.15g \< 24-hour urinary protein quantification \< 3.5g; * No treatment with Huaier Granules within one month prior to enrollment; * Expected survival time not less than 6 months; * Voluntary participation in this study and provision of signed informed consent. Exclusion Criteria: * Known allergy, contraindication, or caution to any component of Huaier Granules; * Inability to take oral medication; * Required or ongoing use of drugs known to potentially affect proteinuria, including but not limited to ACE inhibitors, glucocorticoids (\>3 weeks), and Chinese patent medicines (as per respective drug prescribing information); * Proteinuria caused by underlying diseases, including but not limited to nephropathy, hypertension, urinary tract infection, systemic lupus erythematosus, multiple myeloma, etc.; * Women who are pregnant, breastfeeding, or planning pregnancy; * Currently participating in other clinical trials investigating drugs for treating proteinuria; * Refusal to cooperate with follow-up; * Any other reasons deemed by the investigator as unsuitable for participation in this study.